US2006058300A1PendingUtilityA1
Intermediates of bupropion metabolites synthesis
Est. expiryMar 1, 2019(expired)· nominal 20-yr term from priority
A61P 43/00A61P 25/04A61P 25/24A61P 25/34A61P 25/16A61P 25/28A61P 25/18A61P 25/00A61P 25/20A61P 25/08A61P 1/08A61P 15/10A61P 13/00A61P 15/00A61P 13/10A61K 31/415A61K 45/06A61K 31/435A61K 31/46A61K 31/00A61K 31/5375A61K 31/535C07C 215/30A61K 31/135C07C 49/84A61K 31/165C07C 45/63A61K 31/137C07C 45/511C07D 265/32A61K 31/43A61K 31/53A61K 31/465A61K 31/50C07C 225/16C07C 69/76C07C 213/00C07B 2200/07A61K 31/537
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, sexual dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. Methods of making optically pure bupropion metabolites are also disclosed.
Claims
exact text as granted — not AI-modified1 - 126 . (canceled)
127 . A compound which is (−)-(R,R)-di-p-toluoyl-L-tartaric acid (L-DTTA).
128 . A compound which is (+)-(S,S)-di-p-toluoyl-D-tartaric acid (D-DTTA).Join the waitlist — get patent alerts
Track US2006058300A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.